# Arialys Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arialys-therapeutics

- Industry: Biotechnology
- Headquarters: La Jolla, US
- Website: www.arialysrx.com
- Total disclosed funding: $58M
- Latest round: Seed (Sep 12, 2023)
- Investors on record: 5

## About

Based in California, US, and founded in 2022 by its CSO Mitsuyuki Matsumoto, Arialys Therapeutics, Inc. operates as a biotechnology company dedicated to advancing the treatment landscape for autoimmune neuropsychiatric diseases. In September 2023, Arialys Therapeutics, Inc. raised USD 58 million in seed funding from Alexandria Venture Investments, Avalon Bio Ventures, Catalys Pacific, Johnson & Johnson Innovation, and MPM BioImpact. As of September 2023, the company is led by its CEO Jay Lichter.

Arialys Therapeutics has developed a therapeutic called ART5803, an antibody designed to address anti-NMDA receptor encephalitis (ANRE), a life-threatening neurological disease linked to NMDA receptor autoantibodies. ART5803 decreases the behavioral symptoms caused by NMDAR autoantibody pathogenicity in the brain.

The company plans to use the seed funding to support the advancement of pathogenic autoantibody medicines and the expansion of treatment for neuropsychiatric diseases.

## Funding rounds

- Seed, Sep 12, 2023, $58M — Alexandria Venture Investments, Johnson & Johnson Innovation, MPM BioImpact, Catalys Pacific, Avalon Bio Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Seed
- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Seed
- Avalon Bio Ventures (https://capitalatlas.ai/funds/avalon-bio-ventures) — Seed